London, UK; Brentwood, TN; 2 November 2007 - Protherics PLC (“Protherics” or the Company”), the international biopharmaceutical company focused on critical care and cancer, announces that, today, €300,000 nominal value of Unsecured Convertible Loan Notes 2026 (the “Loan Notes”) were issued to CoVaccine B.V. (“CoVaccine”), under the terms of an agreement between CoVaccine and Protherics for the acquisition of CoVaccine’s novel adjuvant CoVaccine HT™, details of which were announced on 7 June 2006. The Loan Notes are issuable following the attainment of the first development related milestone represented by the agreement between Protherics and Nobilon International B.V. for the licensing of CoVaccine HT™ for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.
